1 ratings / 4 average


Ramos ER, Jiang Y, Hachem R et al. Oncologist 2011;16:1049–60.

This is a retrospective chart review of 449 patients with invasive aspergillosis in the setting of hematological malignancy with or without hematopoietic stem cell transplantation. Treatment with azoles in primary or salvage therapy was associated with a better treatment response and survival rate than if azoles were not used at all.


In this study, the investigators aimed to determine the prognostic factors of invasive aspergillosis (IA) in patients with hematological malignancies. In total, 449 patients with hematological malignancy and proven/probable IA were included. The most common underlying disease was leukemia (75%). Hematopoietic stem cell transplantation (HSCT) had been performed in 172 patients <1 year before diagnosis of IA. Additional risk factors included persistent neutropenia (25%) and steroid therapy (82%). Most patients (71%) received a lipid formulation of amphotericin B, either alone or in combination with other antifungal agents. Azoles and echinocandins were used in 45% and 44% of cases, respectively.

Return to top